HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norov... HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. 더 보기
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus...
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -2 | 2 | 2.036 | 1.86 | 141332 | 1.94478648 | CS |
4 | -0.09 | -4.39024390244 | 2.05 | 2.08 | 1.86 | 170383 | 1.94474392 | CS |
12 | 0.0599 | 3.1524656597 | 1.9001 | 2.15 | 1.78 | 249037 | 1.95654395 | CS |
26 | 0.36 | 22.5 | 1.6 | 2.15 | 1.58 | 260903 | 1.87033775 | CS |
52 | -12.73 | -86.6575901974 | 14.69 | 20.22 | 1.55 | 425596 | 3.99335798 | CS |
156 | -16.8 | -89.552238806 | 18.76 | 24.42 | 1.55 | 215455 | 7.15140321 | CS |
260 | -16.8 | -89.552238806 | 18.76 | 24.42 | 1.55 | 215455 | 7.15140321 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관